机构：[1]Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China首都医科大学宣武医院
出处：
ISSN：
摘要：
Background and Aims: Edaravone dexborneol (EDB) has been verified
multitarget cytoprotective effects and is widely used in China. We aimed
to evaluate the effectiveness and safety of EDB in patients with AIS in real-world clinical practice.
第一作者机构：[1]Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Mo R.,Ma G.,Hao J..EFFECTIVENESS AND SAFETY OF EDARAVONE DEXBORNEOL IN ACUTE ISCHEMIC STROKE: A PROSPECTIVE, REAL-WORLD COHORT STUDY[J].INTERNATIONAL JOURNAL OF STROKE.2024,19(2):67-67.
APA：
Mo, R.,Ma, G.&Hao, J..(2024).EFFECTIVENESS AND SAFETY OF EDARAVONE DEXBORNEOL IN ACUTE ISCHEMIC STROKE: A PROSPECTIVE, REAL-WORLD COHORT STUDY.INTERNATIONAL JOURNAL OF STROKE,19,(2)
MLA：
Mo, R.,et al."EFFECTIVENESS AND SAFETY OF EDARAVONE DEXBORNEOL IN ACUTE ISCHEMIC STROKE: A PROSPECTIVE, REAL-WORLD COHORT STUDY".INTERNATIONAL JOURNAL OF STROKE 19..2(2024):67-67
